This site is intended for healthcare professionals

FDA approves Dojolvi for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders. _Ultragenyx.

Read time: 1 mins
Last updated:16th Mar 2021
Published:4th Jul 2020
Condition: Fatty Acid Oxidation Disorders
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest